1. Home
  2. Labeler Index
  3. Genentech, Inc.
  4. 50242-151
  5. NDC Package Code: 50242-151-01 Ocrelizumab

NDC Package 50242-151-01 Ocrelizumab

Injection - View Billable Units, 11-Digit Format, RxNorm

Table of Contents

    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
50242-151-01
Package Description:
120 L in 1 TANK
Product Code:
50242-151
Non-Proprietary Name:
Ocrelizumab
Substance Name:
Ocrelizumab
Usage Information:
Ocrelizumab is used to treat certain forms of multiple sclerosis-MS (relapsing or primary progressive forms). It is not a cure for MS, but it is thought to help slow down nerve damage, reduce the number of relapses, and delay disability. Ocrelizumab belongs to a class of drugs known as monoclonal antibodies.
11-Digit NDC Billing Format:
50242015101
Product Type:
Drug For Further Processing
Labeler Name:
Genentech, Inc.
Dosage Form:
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Active Ingredient(s):
  • OCRELIZUMAB 300 mg/.01L
    • Sample Package:
    N/A
    Marketing Category:
    DRUG FOR FURTHER PROCESSING - A drug (other than the bulk ingredient API) that is in an interim stage of manufacture, processing, preparation, or packaging, and not ready for human or animal use.
    Start Marketing Date:
    03-28-2017
    Listing Expiration Date:
    12-31-2024
    Exclude Flag:
    N
    Unfinished Product:
    Yes
    Code Structure:

    The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

    * Please review the disclaimer below.

    Other Product Packages

    The following packages are also available for this product:

    NDC Package CodePackage Description
    50242-151-02300 L in 1 TANK

    * Please review the disclaimer below.

    Frequently Asked Questions

    What is NDC 50242-151-01?

    The NDC Packaged Code 50242-151-01 is assigned to an UNFINISHED drug package of 120 l in 1 tank of Ocrelizumab, drug for further processing labeled by Genentech, Inc.. The product's dosage form is injection and is administered via form.

    Is NDC 50242-151 included in the NDC Directory?

    Yes, Ocrelizumab is an UNFINISHED PRODUCT with code 50242-151 that is active and included in the NDC Directory. The product was first marketed by Genentech, Inc. on March 28, 2017 and its listing in the NDC Directory is set to expire on December 31, 2024 if the product is not updated or renewed by the manufacturer.

    What is the 11-digit format for NDC 50242-151-01?

    The 11-digit format is 50242015101. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

    This package code is originally configured in a 5-3-2 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

    10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
    5-3-250242-151-015-4-250242-0151-01